» Articles » PMID: 20200384

Glycated Hemoglobin, Diabetes, and Cardiovascular Risk in Nondiabetic Adults

Overview
Journal N Engl J Med
Specialty General Medicine
Date 2010 Mar 5
PMID 20200384
Citations 613
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Fasting glucose is the standard measure used to diagnose diabetes in the United States. Recently, glycated hemoglobin was also recommended for this purpose.

Methods: We compared the prognostic value of glycated hemoglobin and fasting glucose for identifying adults at risk for diabetes or cardiovascular disease. We measured glycated hemoglobin in whole-blood samples from 11,092 black or white adults who did not have a history of diabetes or cardiovascular disease and who attended the second visit (occurring in the 1990-1992 period) of the Atherosclerosis Risk in Communities (ARIC) study.

Results: The glycated hemoglobin value at baseline was associated with newly diagnosed diabetes and cardiovascular outcomes. For glycated hemoglobin values of less than 5.0%, 5.0 to less than 5.5%, 5.5 to less than 6.0%, 6.0 to less than 6.5%, and 6.5% or greater, the multivariable-adjusted hazard ratios (with 95% confidence intervals) for diagnosed diabetes were 0.52 (0.40 to 0.69), 1.00 (reference), 1.86 (1.67 to 2.08), 4.48 (3.92 to 5.13), and 16.47 (14.22 to 19.08), respectively. For coronary heart disease, the hazard ratios were 0.96 (0.74 to 1.24), 1.00 (reference), 1.23 (1.07 to 1.41), 1.78 (1.48 to 2.15), and 1.95 (1.53 to 2.48), respectively. The hazard ratios for stroke were similar. In contrast, glycated hemoglobin and death from any cause were found to have a J-shaped association curve. All these associations remained significant after adjustment for the baseline fasting glucose level. The association between the fasting glucose levels and the risk of cardiovascular disease or death from any cause was not significant in models with adjustment for all covariates as well as glycated hemoglobin. For coronary heart disease, measures of risk discrimination showed significant improvement when glycated hemoglobin was added to models including fasting glucose.

Conclusions: In this community-based population of nondiabetic adults, glycated hemoglobin was similarly associated with a risk of diabetes and more strongly associated with risks of cardiovascular disease and death from any cause as compared with fasting glucose. These data add to the evidence supporting the use of glycated hemoglobin as a diagnostic test for diabetes.

Citing Articles

Brazilian guideline for screening and diagnosis of type 2 diabetes: a position statement from the Brazilian Diabetes Society.

Rodacki M, Zajdenverg L, da Silva Junior W, Giacaglia L, Negrato C, Cobas R Diabetol Metab Syndr. 2025; 17(1):78.

PMID: 40038723 PMC: 11881304. DOI: 10.1186/s13098-024-01572-w.


Nonlinear association between glycated hemoglobin levels and mortality in elderly patients with non-diabetic chronic kidney disease: a national health and nutrition examination survey analysis.

Huang L, He L, Zeng Q, Huang J, Luo X, Zhong Q Front Endocrinol (Lausanne). 2025; 16:1416506.

PMID: 40007805 PMC: 11850242. DOI: 10.3389/fendo.2025.1416506.


Association of Hemoglobin A1c Levels With All-Cause Mortality in Patients With Coronary Artery Disease: The Essen Coronary Artery Disease Registry.

Dykun I, Kappo N, Kampf J, Babinets O, Janosi R, Totzeck M JACC Adv. 2025; 4(3):101624.

PMID: 39985886 PMC: 11904530. DOI: 10.1016/j.jacadv.2025.101624.


Association between glycation gap and impaired cardiorespiratory fitness: evidence from American adults.

Fei M, Wu B, Tu J, Chen H, Guo Y BMC Cardiovasc Disord. 2025; 25(1):119.

PMID: 39979808 PMC: 11840999. DOI: 10.1186/s12872-025-04578-y.


Poorly controlled type II diabetes mellitus significantly enhances postoperative chemoresistance in patients with stage III colon cancer.

Guan R, Wu J, Yuan Z, Liu Z, Liu Z, Xiao Z World J Gastroenterol. 2025; 31(3):98688.

PMID: 39839894 PMC: 11684163. DOI: 10.3748/wjg.v31.i3.98688.


References
1.
Stout R, Fulks M, Dolan V, Magee M, Suarez L . Relationship of hemoglobin A1c to mortality in nonsmoking insurance applicants. J Insur Med. 2008; 39(3):174-81. View

2.
Levitan E, Liu S, Stampfer M, Cook N, Rexrode K, Ridker P . HbA1c measured in stored erythrocytes and mortality rate among middle-aged and older women. Diabetologia. 2007; 51(2):267-75. PMC: 2757266. DOI: 10.1007/s00125-007-0882-y. View

3.
Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M . Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008; 358(24):2560-72. DOI: 10.1056/NEJMoa0802987. View

4.
Gerstein H, Miller M, Byington R, Goff Jr D, Thomas Bigger J, Buse J . Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008; 358(24):2545-59. PMC: 4551392. DOI: 10.1056/NEJMoa0802743. View

5.
Gerstein H, Swedberg K, Carlsson J, McMurray J, Michelson E, Olofsson B . The hemoglobin A1c level as a progressive risk factor for cardiovascular death, hospitalization for heart failure, or death in patients with chronic heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality.... Arch Intern Med. 2008; 168(15):1699-704. DOI: 10.1001/archinte.168.15.1699. View